Komori
Annual Securities Report2342TRANSGENIC GROUP INC.Services

Annual Securities Report — FY2025

What TRANSGENIC GROUP INC. reported for the period from 2025-04-01 to 2026-03-31.

How much it says
70Detailed
What moved here
27named for the first time
Its own wording
47terms
Which filing this is
34/ 34newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the consolidated fiscal year, the Group expanded higher-value-added services and pursued cost reductions in the drug discovery support business, improving operating income. However, it recorded extraordinary losses, including business restructuring losses and compensation payments related to falsified contract-testing data at a subsidiary, resulting in a net loss attributable to owners of the parent. The Group also decided to relocate, consolidate and close the Kobe Research Institute.

Komori's summary of this document, not the document's own words.
70Detailed
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
Magnitude of Change
61
Detailed
Strategic Shift
88
Very detailed
Capital Movements
75
Very detailed
Disclosure Gaps
40
Thin
Concentration Risk
100
Very detailed
Future Commitments
68
Detailed
Change in Risk
55
Typical
Financial and Capital Policy
100
Very detailed
Specificity of Disclosure
60
Detailed
Product portfolio
55
Typical
Technology Position
50
Typical
Confidence in Strategic Bets
R&D spend34百万円Money spent making new things.
Cash left over77百万円Cash from the business, less what went into equipment.
Spent on equipment0百万円Plants, machines — things meant to last.
Employees227Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
TRANSGENIC GROUP INC. — FY2025 | Komori